Recorded in January 2020, we spoke with Sachin Chandran, who is currently Executive Director and Head of Pharmaceutical Sciences at Catabasis Pharmaceuticals, Inc. in Boston. Sachin’s responsibilities include oversight of CMC, Tech-Ops and supply chain along with matrixed interactions with regulatory, quality, biology, clinical and commercial. Working in a lean organization and a virtual environment, Sachin brings a strategic mindset while operationalizing with a can-do attitude with the goal to aid in the successful development and commercialization of edasalonexent.

Previously, Sachin has been at Vertex Pharmaceuticals, Inc. and Bristol Myers Squibb Co. in roles of increasing responsibility, courtesy of which he is well-versed in the development of oral dosage forms, biologics and injectables, and inhalation. Over the course of his career, Sachin has been involved in the advancement of new therapies for diseases such as Alzheimer’s, and rare diseases like Cystic Fibrosis and Duchenne Muscular Dystrophy.

Sachin holds a Ph.D. in Chemical and Biomolecular Engineering from the Johns Hopkins University where his graduate work was focused on new modalities in the treatment of prostate cancer.